Jim Simons
ROSG

Jim Simons’s Rosetta Genomics Ltd. ROSG Stock Holding History

Jim Simons’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,533
Closed -$65K – 3246
2014
Q3 		$65K Buy
+1,533
New +$69.7K ﹤0.01% 2698

Other funds holding ROSG

HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jim Simons's ROSG Position: Q4 2014 in Review

Jim Simons sold out of Rosetta Genomics Ltd. (ROSG) in Q4 2014, closing a stake of 1,533 shares — an estimated $65K sold.

Jim Simons first reported a position in ROSG in Q3 2014 and held it in 1 quarter. The position peaked at $65K in Q3 2014. 16 funds tracked by Wall St. Rank hold ROSG as of Q4 2014.

  • Jim Simons reported no remaining Rosetta Genomics Ltd. position as of Q4 2014 after selling out during the quarter.
  • Jim Simons sold 1,533 Rosetta Genomics Ltd. shares in Q4 2014, an estimated $65K.
  • Jim Simons first reported a position in Rosetta Genomics Ltd. in Q3 2014 and held it in 1 quarter.
  • Jim Simons's Rosetta Genomics Ltd. position peaked at $65K in Q3 2014.
  • 16 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q4 2014.

Based on Renaissance Technologies's 13F filing for Q4 2014, filed 13 Feb 2015.